|Articles|December 15, 2019
- BioPharm International-12-15-2019
- Volume 2019 eBook
- Issue 5
Lessons from FDA 483s and cGMP Inspection Data
Production and process controls, organization and personnel were the top problems found, while packaging and labeling citations increased in 2017 and 2018.
Advertisement
An analysis of from Form 483 observations issued by FDA during routine investigations of finished drug and API manufacturing sites provide pharmaceutical quality compliance professionals, managers, and operators with insights into how they can best strengthen compliance and develop appropriate solutions for key regulatory compliance issues.
Article Details
BioPharm International
eBook: Regulatory Sourcebook, December 2019
December 2019
Pages: 6–9
Citation
When referring to this article, please cite it as A. Shanley, “Moving from Compliance to Quality," BioPharm International Regulatory Sourcebook eBook (December 2019).
Articles in this issue
almost 6 years ago
Revision Process for Global/National Pharmacopoeias (eBook)almost 6 years ago
Warning Letters Signal Steps to Compliancealmost 6 years ago
Resources, Guidelines, and Guidance Documentsalmost 6 years ago
Regulatory and Standard Setting Organizationsalmost 6 years ago
Quality Risk Management Plans Create Effective Quality SystemsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
